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Methods of determining insulin sensitivity that use an oral challenge of glucose are preferred to those using intravenous
administration since the measurement is made in conditions more akin to normal physiology. One previously reported protocol
(ODILE) studies glucose uptake in isolation from absorption and endogenous production by the intravenous administration of
tracer approximately forty-five minutes after the oral dose is given. However, this methodology has not been validated against
other accredited procedures. This study utilizes the euglycemic hyperinsulinemic clamp in order to validate the ODILE method.
1. Introduction
The determination of the parameters of glucose metabolism,
and in particular peripheral insulin sensitivity, is of great
interest to clinicians and researchers interested in the aeti-
ology of type 2 diabetes and the metabolic syndrome. Cur-
rently, there are two procedures accredited with providing
estimates of peripheral insulin sensitivity on a cardinal scale
[1]: the euglycaemic clamp [2] and the intravenous glucose
tolerance test (IVGTT) interpreted via the minimal model
[3].The clampmethodology is clinically intensive and usually
applicable only to studieswith relatively few subjects (𝑛 < 20).
The IVGTT is more widely employed and has been used
in intervention studies with many hundreds of participants
[4, 5].The IVGTT, however, fails to conform toGroop’s [6] list
of desirable properties of a methodology to measure insulin
sensitivity, inasmuch as it creates unphysiological conditions.
Intravenous administration of a glucose bolus gives an almost
instantaneous increase in plasma glucose from basal (fasting)
levels to a condition where the renal threshold is frequently
exceeded, and because of the transitory nature of the glucose
input, the period of hyperglycemia is generally less than one
hour in normal subjects. During this time, the concentration
of glucose in the peripheral circulation exceeds that in
the portal vein, in contrast to normal post-prandial condi-
tions. As a consequence, only first phase insulin secretion
can be reliably determined, yet such a response never occurs
in isolation in the normal state. Secondly, in the absence
of incretin effects, the endogenous insulin response is too
small (∼200 pM) and too transitory to be a satisfactory
stimulus for peripheral glucose uptake. Although the latter
can be ameliorated to some extent by exogenous insulin
administration [7], this removes the physiological conditions
of the test even further from reality.
These objections could be overcome if oral administra-
tion of the glucose load is incorporated into the test. The
major drawback of this approach when compared with the
IVGTT is that the rate of appearance of glucose in the blood
is unknown with oral dosing, and separation of the kinetics
of appearance and disappearance is not possible without
additional information or assumptions. The incorporation of
a small bolus dose of labeled glucose near to the maximum
hyperglycaemia has been proposed as a method of overcom-
ing this [8]. A report of proof of principle demonstrated
that such a test gave repeatable estimates of peripheral
insulin sensitivity but was unable to validate the new test
(originally called the OSIVGTT, but more recently renamed
ODILE for Oral Dose Intravenous Label Experiment) by
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comparison with an established technique. Here, we report
such a validation using a stable-labeled euglycaemic clamp as
the reference method.
2. Materials and Methods
2.1. Subjects. Twelve healthy nonobese volunteers aged 18–35
years with body mass index in the range 20–30 kgm−2 were
recruited in the study by advertisement. Written informed
consent was obtained from each subject. The study was
approved by Cambridge Local Research Ethical Committee.
All the volunteer work took place in theWellcomeTrust Clin-
ical Research Facility, Addenbrooke’s Hospital, Cambridge.
Each volunteer underwent a hyperinsulinaemic euglycaemic
clamp and an Oral Dosing Intravenous Labeled Experiment
(ODILE) in random order within 15 days of each other.
2.2. Test Protocols
2.2.1. Hyperinsulinaemic Euglycaemic Clamp. Subjects were
admitted to the ward at 07:00 h following an overnight
fast. Blood sampling via an indwelling cannula began at
07:45 h. and continued for 5.25 h. Three basal blood samples
were drawn between 07:45 and 08:00 h., and then a single-
step hyperinsulaemic euglycaemic clamp study was per-
formed. A primed (930 𝜇mole) infusion (9.3𝜇mole⋅min−1) of
[6, 6]-2H
2
-glucose was administered throughout the clamp
procedure to determine the degree of suppression of endoge-
nous glucose production. A 2.5 h stabilization period was
allowed during which two further blood samples were taken
at 09:00 and 10:00 h, before the normoinsulnemia study
phase of the clamp was begun, where seven blood samples
were taken at five minute intervals, starting at 10:30 h. At
the end of this sampling period, a primed (17.5 pmole⋅kg−1)
infusion (3.5 pmole⋅min−1)⋅kg−1) of insulin was begun and
continued until the end of the clamp study. The insulin
dose was chosen to raise plasma insulin concentrations
by ∼200 pmole⋅L−1, while the serum glucose remained at
the pretest level (∼4mmole⋅L−1). During the period of
hyperinsulinaemia, blood glucose was determined every five
minutes, andmaintained at themean level determinedduring
the normoinsulinemia phase by a variable rate infusion of
20% glucose solution enriched with 0.7% of the [6, 6]-2H
2
-
glucose tracer. After a stabilization period of 1.5 h, seven
blood samples were taken, one every five minutes, to charac-
terize the hyperinsulinaemic phase, and complete the clamp
study.The infusions were then terminated, the cannulae were
removed, and the subject was given breakfast.
Serum glucose concentrations were measured using a
model 2300 STAT Plus Glucose and Lactate analyzer (YSI,
Yellow Springs, Ohio, USA), which uses whole blood and
has a precision of ±0.2mmol/L at normal fasting levels.
Plasma insulin concentration was measured using ELISA
(DSL, Webster, Texas, USA) according to the manufacturer’s
instructions.
Isotopic composition of the glucose was determined
using the 𝛼-D-glucofuranose cyclic 1,2 : 3,5-bis (methyl
boronate)-6-trifluoroacetate derivative [9] using a 5973 mass
selective detector (Agilent Technologies, Palo Alto, Califor-
nia, USA).The spectral region at 240–242Thwas monitored,
and the isotopic composition of the glucose was determined
by using a fitting algorithm [10].
2.2.2. ODILE. The protocol for the ODILE test has been
described previously [8]. The procedure can be described
as a standard oral glucose tolerance test, modified by the
addition of an intravenous bolus of 1.38mmole (250mg)
[1]-13C-glucose administered 45 minutes after the oral glu-
cose has been taken. Blood samples are taken at −15, −10, −1,
15, 30, 45, 46, 47, 48, 49, 50, 51, 53, 55, 57, 59, 61, 63, 65, 70,
75, 80, 85, 90, 95, 100, 105, 115, 125, 135, 150, 165, 180, and 225
minutes after oral dosing.
Glucose and Insulin measurements were made as for
the clamp. 13C isotopic composition of the glucose was
determined by GC/C/IRMS on an Isoprime instrument
(Micromass UK Ltd., Manchester, England) with a CuO
packed combustion furnace operating at 850∘C. The ratio of
the 44 and 45Th isotopologues of the generated CO
2
was
determined using the method of Bluck and Coward [11], and
these were converted [12, 13] to tracer/tracee ratios using
a derived value for pure tracer of 8991Ğ for the glucose
derivative used in this work.
The data obtained were interpreted by the two-
compartment minimal model [14–16] as implemented
by Bluck et al. [8]. The structure of this model is shown
in Figure 1. Glucose is described as existing in two freely
interchanging compartments, with insulin independent
uptake occurring from the accessible pool by two routes. The
first of these corresponds to saturated GLUT2 transport and
is represented by a constant flux, whilst the second describes
nonsaturated transport via GLUT1 and GLUT3, and is
therefore first order (linear) in the quantity of glucose in the
pool. Insulin assisted (GLUT4) uptake is assumed to occur
only from the inaccessible pool. In common with the other
minimal models, insulin is also assumed to be distributed
between two pools, acting from the inaccessible (remote) one.
The model is specified by three differential equations:
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(1)
𝑈
0
is a term denoting a constant (time-independent) con-
tribution to glucose uptake, and 𝐻 is endogenous glucose
production. Note that there has been considerable care
to maintain the distinction between the concentration of
glucose in the accessible pool, [𝐺
1
], and the total quantity in
the remote pool, 𝐺
2
.
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Figure 1: The two-compartment minimal model.
In common with all such models, reparameterization to
obtain an expression for insulin action is desirable: in this case
we adopt that proposed by Mari [17].
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Which leads to the equivalent set of equations:
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It can be shown [14] that this model is not identifiable by
a labeled bolus delivered to the accessible glucose pool, and,
therefore, two internal constraints are required.These require
consideration of the basal (equilibrium) state, from which it
is derived that
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The proposed internal constraints [15] give further rela-
tionships between the parameters:
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where 𝛼 and 𝛽 have fixed values of 0.465 and 3, respectively.
The kinetics for the labeled material injected during the test
are then described by
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The kinetics are therefore described in terms of five
unknownmacroparameters,𝑉
1
, 𝑘
21
, 𝑘
12
, 𝑘
0𝑅
, and 𝜅.These are
found by nonlinear least-squares fitting of the model to the
experimentally obtained data.
The indices describing glucose effectiveness 𝑆
𝐺
and
insulin sensitivity 𝑆
𝐼
are derived [16] from the macroparam-
eters.
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2.2.3. Other Measures. The Matsuda or Composite Index
of Insulin Sensitivity [18] was determined using the basal
glucose and insulin data and that taken at 30, 59, 90, and 125
minutes of the oral test. Body Composition was determined
using DXA (GE Lunar Prodigee).
2.2.4. Statistical Analysis. Measured parameters are quoted
as mean ± standard error. Derived parameter values are
quoted as mean values with maximum and minimum values
following in parentheses. All comparisons are made using
nonparametric methods, principally Spearman correlation.
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Table 1: Subject characteristics. Fat mass and Lean mass (kg)
obtained from DXA measurement.
ID Sex Age (y) Height (m) Weight (kg) Fat mass Lean mass
A F 31 1.58 50.5 14.5 34.2
B M 22 1.84 79.5 11.4 64.5
C M 24 1.76 70.5 4.1 62.9
D M 21 1.80 91.1 20.0 67.6
E F 22 1.65 55.8 13.8 39.9
F F 23 1.65 62.2 20.9 38.5
G M 23 1.78 86.2 24.9 57.6
H M 20 1.79 75.0 19.8 52.1
I M 21 1.78 80.0 25.5 51.7
J M 28 1.75 88.2 37.8 47.9
K M 22 1.86 81.1 6.9 70.9
Table 2: Parameters of glucose metabolism derived from the clamp
and the OSIVGTT.
ID M/I(min−1)
𝑆
𝐺
(min−1)
𝑆
𝐼
(L⋅pmole⋅min−1)
A 9001 0.0259 1.76 × 10−4
B 16567 0.0126 1.96 × 10−4
C 16197 0.0138 1.97 × 10−4
D 35674 0.0215 3.13 × 10−4
E 1584 0.0201 1.07 × 10−4
F 5996 0.0126 1.19 × 10−4
G 7305 0.0149 1.80 × 10−4
H 19438 0.0151 2.09 × 10−4
I 10627 0.0168 2.33 × 10−4
J 5986 0.0143 2.02 × 10−4
K 19920 0.0220 3.51 × 10−4
3. Results
Eleven volunteers (three female) were recruited for the study.
The subject characteristics are shown in Table 1.
As expected, clamp-derived endogenous glucose produc-
tion (EGP) in the basal state was strongly correlated with
weight (𝑟
𝑠
= 0.909, 𝑃 < 0.001), with the weight normalized
average of 1.94 (1.48–2.08)mg/kg/min. The mean plasma
insulin concentration during the clamp phase was 139 ±
6 pmole⋅L−1. In all the subjects except for one, this level of
hyperinsulinaemia was sufficient to suppress EGP by 82±7%.
The𝑀/𝐼 indices of insulin sensitivity for the subjects are
presented in Table 2.This clamp index is positively correlated
with Lean Body Mass (𝑟
𝑠
= 0.782, 𝑃 < 0.01) and negatively
correlated with fraction of body fat (𝑟
𝑠
= −0.627, 𝑃 < 0.05).
However, there is no significant relationship with either
weight (𝑟
𝑠
= 0.36) or with BMI (𝑟
𝑠
= 0.16). Estimates of
insulin sensitivity from the clamp and the Matsuda index
were correlated (𝑟
𝑠
= 0.55), although this did not quite
achieve significance with this number of subjects.
The indices of glucose parameters obtained from the
ODILE test are given in Table 2. In contrast to the orig-
inal formulation of the two compartment model [14], the
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Figure 2:Comparison of the estimates of insulin sensitivity from the
ODILE test and the clamp.The point outlined represents the subject
for which EGP suppression was not achieved during the clamp.
improved parameterization [15] adopted here forces plasma
clearance rate to bear a fixed ratio of 1/(1 − 𝛼) to 𝑆
𝐺
, and
therefore the latter parameter is not reported.Themean value
of glucose effectiveness was 0.172 (0.0126–0.0259)min−1 and
that of insulin sensitivity 2.07 × 10−4(1.07 × 10−4–3.51 ×
10
−4
) L⋅pmole⋅min−1. The two parameters were uncorrelated
(𝑟
𝑠
= 0.31).
Although 𝑆
𝐺
was not related to any body composi-
tion parameter, in contrast, there was a strong relationship
between 𝑆
𝐼
and lean body mass (𝑟
𝑠
= −0.700, 𝑃 ∼0.02); the
correlation of insulin sensitivity with BMI was stronger than
that observed with the clamp estimate and that with percent
body fat weaker, with neither achieving statistical significance
for 𝑆
𝐼
.
The estimates of insulin sensitivity from the clamp and
ODILE test (𝑀/𝐼 and 𝑆
𝐼
) were highly correlated (𝑟
𝑠
= +0.764,
𝑃 < 0.05), Figure 2. Least-squares fitting produced a line
which had a significant intercept with the 𝑆
𝐼
axis.
4. Discussion
The development of tests, which provide rigorous estimates
of the parameters of glucose disposal and production under
normal physiological conditions, is of great interest to both
clinicians and epidemiologists interested in the pathology of
type 2 diabetes. However, the application and interpretation
of such tests require care since insulin has two distinct modes
of action. Firstly, it accelerates glucose disposal by increasing
the number of plasma membrane glucose transporters. This
takes place mainly in nonhepatic tissue. Secondly, insulin
signals to the liver to shift the balance between the rates
of glucose storage and release into the circulation in favour
of the storage process. Crude models of insulin sensitivity
therefore have two terms, one describing the disposal mech-
anisms (peripheral insulin sensitivity) and one the inhibition
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of endogenous glucose production (EGP) usually referred to
as hepatic insulin sensitivity.
Dysfunctionality in either peripheral or hepatic insulin
sensitivity will contribute to the metabolic disturbance
observed in subjects with impaired glucose tolerance
(IGT), diabetes mellitus (DM), or the metabolic syndrome.
Although it is well-established that both mechanisms are
defective in these states, the relative magnitudes of the
abnormalities in specific states of disease are still a matter for
discussion. Whilst many workers have concluded that the
major contribution to insulin resistance in type 2 diabetes
is in peripheral tissues and indeed direct measurement of
the impairment of glycogen formation in skeletal muscle has
been made [19], there is contrary evidence to suggest that
glucose tolerance is primarily determined by hepatic insulin
sensitivity [20].
Some of this ambiguity may be caused by the nature of
the test used in the insulin sensitivity measurement. Many
tests are performed in the postabsorptive state, where it
has been shown that EGP is normal even in moderately
hyperglycaemic subjects [21]. Currently, there are only two
accreditedmethodologies that are considered to give accurate
measures of insulin sensitivity [1]: the euglycaemic hyper-
insulinaemic clamp and the intravenous glucose tolerance
test (IVGTT) interpreted in terms of the minimal model.
However, neither of these tests are made under conditions
which can be regarded as truly normal physiology. Any study
utilising intravenous administration of glucose or insulin can
be considered to be in “reverse physiology” since the systemic
concentrations of the administered substance will exceed that
in the hepatic portal vein, contrary to the situation found
under free-living.
Oral administration of glucose, either directly as in the
oral glucose tolerance test (OGTT) or in more complex natu-
rally occurring forms as sugars and starches in food, provides
physiologically realistic conditions but introduces consider-
able complexity into the interpretation of the test since now
the plasma glucose concentration profile after dose adminis-
tration becomes the sum of three terms: absorption from the
gastrointestinal tract, endogenous production, and disposal.
This has led investigators to introduce various empirical
methods of obtaining indices of insulin sensitivity from oral
tests {Sluiter, 1976 #1405 Hanson, 2000 #1729; Cederholm,
1990 #1406; Matsuda, 1999 #1163; Belfiore, 1998 #1402}. The
major difficulty with this approach is that at best the results
obtained will be ordinally related. In order to quantitatively
express concepts such as improvements in insulin sensitivity
in response to pharmacological or dietary intervention, it is
required that the data obtained should lie on an interval scale,
and this is best achieved by retaining some sort of physiologi-
cal model which can be rigorously described mathematically.
Recently, we demonstrated the feasibility of a different
approach to obtaining values of insulin sensitivity under the
physiological conditions of an oral glucose dose {Bluck, 2006
#2739}. In our method, which we since renamed the Oral
Dose Intravenous Label Experiment (ODILE), the strategy
adopted is effective to separate the hot and cold glucose doses
given in the hot IVGTT. As in the hot IVGTT [22, 23],
the labelled species are used for the determination of the
metabolic parameters; the associated cold glucose merely
provides the insulin secretory response.
In our new approach, although the major fraction of the
glucose dose is given orally, intravenous administration of the
label was required to circumvent modeling the absorption
characteristics. Secondly, the quantity of labeled material
had to be small enough not to perturb the extant kinetics
of glucose clearance. Whilst this would have been a simple
matter with radiolabel, the quantity of ethically acceptable
deuterated glucose given would have been too great. This led
us to consider changing the method of detection from gas-
chromatography/mass spectrometry (GC/MS) to the more
precise gas chromatography/combustion/mass spectrometry
(GC/C/MS). Recently, we demonstrated that [1]-13C-glucose
was a satisfactory alternative to the customary [6, 6]-2H
2
-
labeled material in the IVGTT for the determination of
glucose metabolism [12, 13] in a wide variety of states of
glucose tolerance [24]. Compound specific 13C isotope ratio
analysis is a well-established technique [25–27] and we were
able to apply it in our desired application using only 250mg
of labeled material.
Our preliminary investigation [8] proved the principle of
the newmethodology, indicating that for intravenous glucose
tolerance tests using the orally stimulated (OSIVGTT) pro-
tocol interpretation using the 2CMMwere not only desirable
but necessary. In addition,we showed that the values obtained
for parameters of glucose metabolism from the OSIVGTT
seemed to be greater than those from the corresponding
IVGTT by a factor of about 2.5.
Although it can be regarded as nonphysiological, and
despite its time-consuming and labor intensive nature, the
euglycaemic hyperinsulinaemic euglycaemic clamp [2] is still
regarded as the method of choice by diabetologists for the
assessment of insulin sensitivity.This is principally because it
is easily interpreted, does not require a model of the glucose
and insulin system, and depends on very few assumptions.
For this reason, any new methodology for estimating insulin
sensitivity is usually validated by the comparison with clamp
techniques, and this is the purpose of this report for the
ODILE method.
The significant correlation achieved between the clamp
andODILEmethod demonstrates that the latter is a valid tool
for the assessment of insulin dependent glucose disposal; this
has been achieved with such a relatively homogenous group
of subjects is particularly encouraging. However, it is of some
concern that the two methods are apparently not measuring
the same metabolic parameter, since the intercept of the plot,
Figure 2, is clearly not equal to zero. This parallels closely the
situation for the IVGTT itself, which has been comparedwith
clamps on a number of occasions [3, 7, 28–31]. A significant
relationship between the IVGTT and clamp was not achieved
in an early study with a very homogenous population [29],
but was later demonstrated when wider spectrums of insulin
sensitivity were investigated [3, 7].
In this context, it should be noted that the relationship
between the clamp andODILEmeasures of insulin sensitivity
remains even when corrected for lean body mass, although
it is slightly weaker (data not shown). This is important as
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although both measures are themselves correlated with lean
bodymass, the observed association is not simply due to cross
correlation.
As in the present investigation, it has been pointed out
that the IVGTT and clamp are correlated, but not measuring
the same metabolic parameter [30]. In the case of the ODILE
test this is perhaps not surprising, given that, unlike in
the clamp, where measurements are made under steady
conditions, in the ODILE test plasma insulin changes in
a continuous manner in response to the pattern of meal-
induced hyperglycaemia, making it likely that the parti-
tioning of the glucose load between the various metabolic
routes is different for the clamp and ODILE in the clamp the
insulin infusion elevated plasma levels to about 140 pmole/L;
in the OSIVGTT this value was exceeded from about 0.5 hr
before the administration of the tracer to 1.5 hr afterwards
and reached a maximum value of 330 pmole/L. During this
period, the dose-response curve for insulin mediated glucose
uptake is near-saturated in splanchnic tissue but not in
muscular organs such as the leg [32], and therefore it might
be expected that insulin sensitivity would be a function of
the plasma insulin profile during the measurement period.
Secondly,ODILE, unlike the clampor IVGTT, operates in cir-
cumstances of normal physiology where the concentrations
of both glucose and insulin are higher in the hepatic portal
vein than in the peripheral systemic circulation.
Under the conditions of ODILE endogenous, insulin is
secreted into the hepatic portal system, and encounters the
liver, where approximately half of the hormone is degraded,
before passing to the peripheral tissues. Elevated portal
insulin has been shown to stimulate glycogenesis by a direct
route, but insulin administered intravenously as in the clamp,
acts primarily by stimulating gluconeogenesis, and thereby
increasing glycogenesis by an indirect route [33]. An effect of
the origin of insulin on estimates of insulin sensitivity derived
from theminimal model has been demonstrated by compari-
son of tolbutamide-modified and insulin-modified tests [34].
Similarly, it has long been known that the route of admin-
istration of glucose has a profound effect on its metabolism
[35]. Under the initial conditions of oral glucose ingestion,
the concentration of glucose in the portal system exceeds that
in the peripheral veins, and animal models indicate that this
portal signal is sufficient to transform liver metabolism from
net glucose production to net storage [36].
5. Conclusions
The ODILE test was invented specifically to apply the power
of tracer methodologies under truly physiologically realistic
conditions. In order to increase its acceptability to the
diabetological community, we have validated the test against
a “gold standard”methodology and demonstrated that, whilst
the tests are not directly comparable, the correlation between
them, even in a relatively homogenous population, is ade-
quate and better than that obtained from an established
interpretation of the oral glucose tolerance test (Matsuda
index). Furthermore, the ODILE test requires considerable
less clinical expertise than the clamp and is more suited to
medium scale studies of glucose metabolism.
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